Keryx Biopharmaceuticals Announces Appointment of Douglass H. Laidlaw, Ph.D., as Director, Medical Affairs
Published: Oct 02, 2013
NEW YORK, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced the appointment of Douglass H. Laidlaw, Ph.D. to the newly created position of Director, Medical Affairs, with oversight of the creation and activities of the Company's Medical Science Liaisons (MSL) team.
Help employers find you! Check out all the jobs and post your resume.